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An inherited deficiency of themitochondrial protein frataxin causes Friedreich’s ataxia (FRDA); themechanism
by which this deficiency triggers neuro- and cardio-degeneration is unclear. Microarrays of neural tissue of
animal models of the disease showed decreases in antioxidant genes, and increases in inflammatory genes.
Cyclooxygenase (COX)-derived oxylipins are important mediators of inflammation. We measured oxylipin
levelsusing tandemmassspectrometryandELISAs inmultiplecell andanimalmodelsofFRDA.Massspectrom-
etry revealed increases inconcentrationsofprostaglandins, thromboxaneB2, 15-HETEand11-HETEincerebellar
samplesof knockin knockoutmice.One possible explanation for the elevated oxylipins is that frataxin deficiency
results in increased COX activity. While constitutive COX1 was unchanged, inducible COX2 expression was
elevated over 1.35-fold (P < 0.05) in two Friedreich’s mouse models and Friedreich’s lymphocytes. Consistent
with higher COX2 expression, its activity was also increased by 58% over controls. COX2 expression is driven
by multiple transcription factors, including activator protein 1 and cAMP response element-binding protein,
both of which were elevated over 1.52-fold in cerebella. Taken together, the results support the hypothesis that
reduced expression of frataxin leads to elevation of COX2-mediated oxylipin synthesis stimulated by increases
in transcription factors that respond to increased reactiveoxygenspecies. Thesefindingssupport aneuroinflam-
matory mechanism in FRDA, which has both pathomechanistic and therapeutic implications.
INTRODUCTION
Friedreich’s ataxia (FRDA) is the most common autosomal
recessive ataxia affecting 1:40 000 individuals (1). The
disease is characterized by the neurodegeneration of dentate
nucleus of the cerebellum and demyelination in spinocerebellar
dorsal root ganglion neurons as well as hypertrophic cardiomy-
opathy and diabetes (2–4). Clinical symptoms of FRDA include
gait ataxia affecting the motor coordination, weakness and
atrophy of the extremities, and loss of lower-limb tendon
reflexes. The disease is caused by reduced expression of frataxin
gene attributed to the repeat expansion of GAA in the first intron
of the gene or point mutation truncating the protein (1,5–7).
Extensive knowledge on the role of oxidative stress in the
pathogenesis of FRDA exists including studies involving
FRDA patient-derived cells and various mouse models. FRDA
patient-derived cells have increased sensitivity to oxidative
stress (8,9), and patients were observed to have increased
markers of oxidative stress in their blood and urine (10–12). Fur-
thermore, reduced Frataxin appears to reduce the level and or
inducibility of Nuclear factor (erythroid-derived 2)-like 2
(NRF2) in cell and animal models of Friedreich’s (13,14),
which has been demonstrated to have anti-inflammatory
effects in other systems patients may impair the induction of
early antioxidant defenses resulting in increased cell lethality
when under oxidative stress. Consistently, studies involving
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transgenic mouse models YG8 and YG22, both expressing
human frataxin with trinucleotide repeat (GAA)≤190 reducing
frataxin transcription showed signs of increased oxidative
stress in the cerebellum, heart and skeletal muscles (14,15).
The prostaglandin (PG) pathway has been shown to be
induced in response to oxidative stress and may be over stimu-
lated by the chronic reactive oxygen species (ROS) elevation
in frataxin-deficient models (16). PGs and thromboxanes are a
subclass of eicosanoids produced by cyclooxygenase (COX)-
mediated conversion of arachidonic acid in response to various
stimuli (17–19). Previously we showed that inflammatory eico-
sanoids including PGs and thromboxane B2 (TXB2) and cyto-
kines rose in frataxin-depleted Schwann cells (20). Consistent
with the induction of inflammation in these frataxin-deficient
cells, the decreased viability of the frataxin-deficient Schwann
cells was rescued by known anti-inflammatory and anti-
apoptotic drugs (20). Of the inhibitors, those targeting P38
kinases were most effective rescuers, suggesting a cAMP re-
sponse element-binding protein (CREB) driven regulation of
PG instigating the rescue in cell viability. Along with CREB,
transcription factors, nuclear factor kappa-light-chain-enhancer
of activated B cells (NFkB) and activator protein 1 (AP1) also
regulate the expression of COX2 (21–23).
Inflammatory changes have been noted in the neurodegen-
erative conditions Alzheimer’s disease (24,25), Parkinson’s
disease (26) and Amyotrophic lateral sclerosis (27,28). Given
the previous implications of inflammatory PGs in cell models
of FRDA pathogenesis, we investigated COX metabolites in
cerebella of FRDA mouse models and patient B-lymphocytes.
Significant differences were observed and an underlying mech-
anism is suggested.
RESULTS
Confirmation of frataxin deficiency inmouse and cellmodels
by qRT–PCR
The cerebellar frataxin deficiency of the mouse frataxin
knockin-knockout (KIKO) mouse was quantified by qRT–
PCR; the animals contained 31% of frataxin compared with
wild type (WT) mice as control (P . 0.0032, n ¼ 4). Similarly,
frataxin levels were quantified in the YG8 hemi and homozygote
(15), and in cellular models of FRDA; all mutants were signifi-
cantly deficient in frataxin. The hemizygote mice expressed
41% of frataxin as homozygote (P . 0.00013, n ¼ 4) and
patient-derived B-lymphocytes expressed 15.9% of frataxin
compared with healthy B-lymphocytes (P. 0.0021, n ¼ 4)
(Fig 1).
Elevation of COX-derived oxylipins in frataxin-deficient
mice
Oxylipins were measured in cerebella of frataxin knock-in/
knockout (KIKO) deficient mice (29) using UPLC–MS/MS
(Fig. 2). We quantified 33 arachidonic acid-derived oxylipins
produced by COXs, lipoxygenases (LOXs) and cytochrome
P450 (CYP). Twelve oxylipins were elevated in the KIKO
mice (P . 0.05, n ¼ 4) (Fig. 2), including the COX-derived
prostanoids, thromboxanes, COX-side products 11 and 15
hydroxyeicosatetraenoic acids (HETE) (30), the CYP-derived
epoxyeicosatrienoic acid (EET) and dihydroxyeicosatrienoic
acid (DHET), and the 5LOX-derived HETE and ketoeico-
satetraenoic acids (17,31,32). The results support the idea that
frataxin deficiency in mice leads to increase in a global inflam-
matory response, including enhanced PG synthesis.
Frataxin-deficient animal and cell models have increased
COX2 expression
To understand the source of prostanoid elevation, we measured
the protein concentration of both COX1 and COX2, the constitu-
tive and inducible COXs, respectively (17,19,33,34). For this
experiment, we utilized three different models of frataxin
deficiency. The first model as described previously is the cere-
bella of KIKO mouse model compared with WT control. The
second model is the cerebella of YG8 mouse model knocked
out for endogenous frataxin gene and inserted with mutant
human frataxin transgene comparing hemizygote with a single
copy of transgene expressing 41.0% that of homozygote (15).
COX 1 and 2 expression were also measured in human
B-lymphocytes isolated from FRDA patients with 16.0%
frataxin expression compared with healthy B-lymphocytes
(P . 0.0020) (Fig. 1). Significantly increased protein levels of
COX2 were observed in frataxin-deficient models, 4.16-fold
in KIKO model (P. 0.0030, n ¼ 4), 1.35-fold in YG8 model
(P. 0.039, n ¼ 4) and 1.92-fold in B-lymphocytes (P. 0.019,
n ¼ 4) while no changes in the expression levels of the constitu-
tive isoform COX1 were detected (Fig. 3A–C).
Upstream of COX 1 and 2 is cytosolic phospholipase 2
(cPLA2), which hydrolyzes and releases arachidonic acid to be
converted into PGG2 by COX. Thus, cPLA2 can potentially
alter the prostanoid profile (19,33). We measured the protein
Figure 1. Reduced frataxin expression in frataxin-deficient models analyzed by
qRT–PCR. Relative expression was normalized to b-actin and control using
DDCT calculation. Cerebellum of KIKO showed 0.317-fold decreased expression
compared with C57Bl/6. Cerebellum of YG8 hemizygotes showed 0.410-fold
decreased expression compared with YG8 homozygote. Patient B-lymphocytes
showed 0.159-fold decreased expression compared with healthy B-lymphocytes.
Bars represent averages+ standard deviations (n ¼ 4, P , 0.005∗, P ,
0.0005∗∗).
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level of both cPLA2 and its active form, phosphorylated at serine
505, and detected no significant difference between KIKO and
WT mouse cerebellum (n ¼ 4) (Fig. 3D). Taken together,
these results support the notion that increased COX2 expression,
rather than COX1 or cPLA2 activity, is the cause of increased
prostanoid levels in frataxin-deficient models.
Increased COX activity in frataxin-deficient mice and cells
In order for an increase of COX expression to impact prostanoid
concentrations, the increase must impact COX activity. Thus we
analyzed the arachidonate metabolites of the KIKO cerebellar
tissue normalized to both total concentration of unbound arachi-
donic acid and also to WT to identify the relative activity of
downstream enzymes. In mutants the COX metabolites were
3.05-fold higher than WT, 15LOX metabolites were 1.94-fold
higher than WT, 5LOX metabolites were 2.24-fold higher than
WT, CYP metabolites were 1.33-fold higher than WT, and
other arachidonic acid metabolites were 1.20-fold higher than
WT (n ¼ 4) (Fig. 4). COX metabolites were significantly
higher than those of 15LOX (P. 0.02), CYP (P. 1.54 ×
1025) and other arachidonate metabolites (P . 1.13 × 1026).
We also observed significant elevation of 5LOX metabolites
compared with CYP (P . 0.03) and other arachidonate metabo-
lites (P . 0.018) (n ¼ 4) (Fig. 4).
We also performed an ELISA-based activity assay measuring
the conversion rate of hydrolyzed arachidonic acid to PGG2, a
precursor to PGH2. Comparing the cerebellum of frataxin-
deficient mouse KIKO and YG8, and patient B-lymphocyte to
either WT or healthy controls, we found significant elevation
of COX activity when normalized to indomethacin-inhibited
samples. KIKO hemizygote showed 1.58-fold activity (P. 0.030,
n¼ 3), YG8 hemizygote showed 2.21-fold activity (P. 0.0012,
n ¼ 4) and patient B-lymphocyte showed 1.92-fold activity
(P. 0.0069, n ¼ 4) relative to their respective controls (Fig. 5).
Taken together with the immunoblot results, the likely driving
force of increased prostanoid concentration in the frataxin-
deficient models is the overexpression and the subsequent
increased activity of COX2.
Elevated CREB and AP1 transcription factors explain
COX2 overexpression in frataxin-deficient cells
Expression of the COX2 gene is driven by multiple positive
factors, including NFkB, CREB and AP1. To understand
whether or how frataxin deficiency was driving an intrinsic in-
crease in COX2 gene activity, we used antibody specific to acti-
vated transcription factors, phosphorylated NFkB (ser536),
phosphorylated CREB (ser133) and phosphorylated AP1
(ser63) known to positively regulate COX2 expression, in the
cerebella of KIKO mouse (21–23). We found no difference in
the activation of NFkB (n ¼ 6) but identified a 3.67-fold increase
in CREB activation (P. 0.0024, n ¼ 6) and 1.52-fold increase
in AP1 activation (P. 0.028, n ¼ 6) (Fig. 6A and B). This sug-
gests that in the context of the frataxin-deficient cerebellum,
CREB and AP1 increase drive the COX2 overexpression and
increased PG production.
Increased microglial activation in lipopolysaccharide
induced frataxin-deficient mouse cerebellum
To understand whether COX2 overexpression and increased
prostanoids were having an impact on neuroinflammation in
the frataxin-deficient context, we measured ionized calcium-
binding adapter molecule 1 (Iba1), a known marker of microglial
neuroinflammation in the cerebella of YG8 mice, in the context
of the experimental inflammogen lipopolysaccharide (LPS)
(20,35). The treatment of WT with LPS did not significantly
increase the expression of Iba1 in cerebellum with 1.16-fold
elevation, but the same treatment in the YG8 hemizygotes
had significantly increased the Iba1 expression by 1.37-fold
(P . 0.0096, n ¼ 4). Accounting for baseline Iba1 expression
in WT and YG8 hemizygote cerebellum treated with PBS,
YG8 hemizygotes had 17% increase in induction of Iba1 by
LPS compared with WT (Fig. 7A and B)]. Thus, frataxin defi-
ciency increased the reactivity of iba 1 staining microglia in
the context of LPS treatment relative to WT.
Figure 2. Inflammatory arachidonic metabolites are elevated in cerebellum of
frataxin-deficient KIKO mouse model. (A and B) 12 arachidonic metabolites
converted by COX, lipoxygenase and cytochrome P450 were identified to be sig-
nificantly increased. Grubbs test was used to exclude outliers assuming normal
distribution. Bars represent averages+ standard deviations (n ¼ 4, P , 0.05∗,
P , 0.005∗∗).
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DISCUSSION
FRDA is an autosomal recessive disease characterized by the
degeneration of the dorsal root ganglion and cerebellum (2,4).
Clinical symptoms of FRDA include gait ataxia affecting the
motor coordination, weakness and atrophy of the extremities,
and loss of lower-limb tendon reflexes (5,36,37). The disease
state is caused by the reduced expression of a nuclear encoded
Figure 3. Frataxin-deficient models have increased expression of COX2 and no alterations in COX1 or cPLA2 expression. (A and D) Cerebellum of KIKO has
4.40-fold increased expression of Cox2 while no changes in Cox1 and cPla2 or the active phosphorylated cPLA2 were observed compared with C57Bl/6 WT. (B)
Cerebellum of YG8 hemizygote showed 1.35-fold increased Cox2 expression and no change in Cox1 expression was observed compared with YG8 homozygote.
(C) Patient B-lymphocytes had 1.71-fold increased expression of COX2 expression with no changes in COX1 expression compared with healthy B-lymphocytes.
The KIKO and YG8 samples were normalized to b-tubulin and B-lymphocyte samples were normalized to b-actin. Bars represent averages+ standard deviations
(n ¼ 4, P , 0.05∗, P , 0.005∗∗).
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gene, frataxin mediated by the repeat expansion of GAA within
the first intron of the gene altering the epigenetic control of the
gene transcription (6,7,38). However, the pathomechanism by
which frataxin deficiency causes neuro- and cardio-degeneration
is not clear. We previously demonstrated inflammatory conse-
quences of frataxin knockdown in Schwann tissue culture cells
(20), and also induction of inflammatory transcripts and suppres-
sion of antioxidant and NRF2 anti-inflammatory molecules in a
mouse model of FRDA (14). The reduced capacity of NRF2 and
thiol antioxidant proteins (Glrx1, Gstm1 and Prdx3) is thought
to be involved in the production of ROS in the cerebellar tissue
and possibly in the lymphocyte cells by suppressing the cell’s
capacity to maintain homeostatic anti-oxidative capability. The
suppression of the anti-inflammatory factor NRF2, and the
elevated expression of the pro-inflammatory prostaglandin D2
synthase (PTGDS) transcript motivated a search for changes in
inflammatory mediators in brains of a Friedreich’s animal model.
Four PGs and TXB2 were elevated significantly in KIKO mice
over controls. Of the elevated eicosanoids, 8 of 12 were the pro-
ducts of COX-mediated conversion of arachidonic acid, support-
ing the notion that the COX activity could play a role (Fig. 2A
and B) (17,31,32). We also observed elevation of LOX and
CYP metabolized products, which have been previously
reported and may be the result of parallel pathway activated by
oxidative stress (24,26,28,39). Many of the non-COX metabolite
mass spectrometry hits including 11,12EET, 15HETrE and
5HETE have been reported to have anti-inflammatory effects
in response to excess production of ROS (40–42). Interestingly,
15LOX and COX mediated metabolite 15HETE is believed to be
involved in the progression of Alzheimer’s disease and the re-
duction of 15HETE in Alzheimer’s model shows evidence of
decreased oxidative stress (32,43). Furthermore, increase of spe-
cific CYPs may also contribute to the compounding problem of
oxidative stress by synthesizing ROS but this effect has yet to be
investigated in the context of FRDA (44). Similar rises in pros-
tanoid synthesis have been reported to have neuroinflammatory
effects leading to neurodegeneration (45). PGs including PGE2
and 15d-PGJ2 have been associated with pathogenesis of neuro-
degenerative diseases such as Alzheimer’s disease (24,25), Par-
kinson’s disease (26) and Amyotrophic lateral sclerosis (27,28).
We also looked into more general lipid composition analysis
to determine whether frataxin deficiency simply elevates lipid
synthesis nonspecifically. Mass spectrometry analysis revealed
only minor elevation of total fatty acid in the KIKO mice com-
pared with those of WT, but the major elevation was observed
in the COX-mediated oxylipid metabolism, supported by
slight decrease in the concentration of linoleic acid (C18:2n6)
in the KIKO mice (Supplementary Material, Fig. S1). The
frataxin-deficient KIKO mouse has increased concentration of
prostanoids synthesized primarily by COX, and this elevation
may contribute to increased inflammation, which may ultimately
lead to degeneration of the dorsal root ganglion and cerebellum.
The action of both COX and cPLA2 play key roles in the syn-
thesis of prostanoids. Initially, cPLA2 regulates the availability
of free arachidonic acid by hydrolysis and cleavage from the
phospholipid bilayer followed by COX-mediated conversion
of arachidonic acid to the prostanoids (17–19,27,46). In this
study we showed by immunoblot analysis of KIKO and YG8
cerebellum as well as B-lymphocyte cells, the likely cause of
prostanoid concentration elevation observed by mass spectrom-
etry (Fig. 2A and B) resulted from the overexpression of the in-
ducible COX isoform, COX2 rather than the constitutive
isoform, COX1 (19,33,34) (Fig. 3A–C). We identified no
Figure4.Frataxin-deficient KIKO mice have elevated COX metabolites normal-
ized to free arachidonic acid relative to WT. All oxylipids downstream of arachi-
donic acid were normalized to total concentration of unbound arachidonic acid
and fold change calculated relative to WT for the same metabolite. The COX me-
tabolism (TXB2, PGF1a, PGE2, PGD2, PGJ2, PGF2a and 11 HETE) was
3.05-fold higher than WT, 15LOX metabolism (15 HETE) was 1.94-fold
higher than WT, 5LOX metabolism (5 HETE) was 2.24-fold higher than WT,
CYP metabolism (14,15DHET and 11,12-DHET) was 1.33-fold higher than
WT, other arachidonate metabolism (8,15DHET, 5,15DHET, 9HETE and
8HETE) was 1.20-fold higher than WT. Bars represent averages+ standard
error mean (n ¼ 4, P, 0.05∗, P, 0.00005∗∗).
Figure 5. Frataxin-deficient models have increased total COX activity of cere-
bellar or B-lypmphocyte lysate. All FRDA models, KIKO, YG8 and patient
B-lymphocytes showed 1.58-, 2.21- and 1.94-fold increase in COX activity re-
spective to each model’s control. Bars represent averages+ standard deviations
(n ¼ 3–4, P , 0.05∗, P , 0.01∗∗).
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alterations in protein concentration of cPLA and phospho- cPLA
in the KIKO mice, indicating that cPLA2 does not cause the
increased prostanoid burden in mutant mice (Fig. 3D) (46).
Total COX activity assays also supported the notion that
COX2 overexpression has increased the conversion rate of ara-
chidonic acid to downstream prostanoids (Fig. 5). These data
are supported by arachidonate metabolite analysis, indicating
that the more of the unbound arachidonic acid is being converted
into downstream metabolites of COX than any other enzyme
(Fig. 4). Both 15- and 5-LOX activity appear to be elevated com-
pared with WT, which may be a consequence of basally elevated
ROS in the frataxin-deficient state (32,42). Taken together, the
reduction in frataxin expression has increased the expression
of COX2 increasing the synthesis of prostanoids. Given the
increased prostanoid profile in the KIKO mouse model, one
could consider the reversal of COX2 overexpression by
NSAIDs, but this was beyond the scope of this work, but is a
future prospect.
COX2 expression is regulated by three transcription factors,
NFkB, CREB and AP1, and of these, we have found increased
activation of CREB and AP1 (22). The CREB and AP1 activation
was 3.67 and 1.52-fold higher in the KIKO mice, respectively, in-
dicating multiple pathway activation of COX2 transcription and
the greater role of CREB in COX2 activation (Fig. 6A and B).
Both CREB and AP1 transcription factors have been reported to
be activated by cytokine pathways mediated through the presence
of ROS (23,47). Interestingly, the chronic elevation of oxidative
stress in FRDA patients and animal models may be a contributing
factor in the activation of cytokines responsible for COX2 overex-
pression (8–12), suggesting the mechanism fxn-deficiency-.
ROS-.cytokines-.CREB/AP1-.COX2-.iba1/microglial
activation-.neuroinflammation-.neurodegeneration (Fig. 8).
It cannot be ruled out that the dysregulation of NRF2 in the
frataxin-deficient mice (14) (Supplementary Material, Fig. S3)
is uninvolved in the overexpression of COX2 as it has previously
been shown to be the case in the brain of Nrf22/2mice and plays
a role in further elevating inflammatory state of frataxin-
deficient mice (48).
One question that arises from these data in Friedreich’s patient
cells and two mouse models is whether evidence of inflammation
is also observed in either living Friedreich’s patients or autoptic
tissue. There is clear evidence of inflammation in Friedreich’s
autoptic hearts marked by cluster of differentiation 68 (CD68)
positive cells (49); CD68 is a marker of microglial activation.
Microglia are more activated in brains of LPS-stimulated
mutant mice than in controls, consistent with a frataxin-
dependent increase in microglial activation in these cerebellar
samples (Fig. 7). These data suggest that frataxin deficiency
leads to microglial activation in Friedreich’s hearts and mouse
model brains. We see increased production of oxylipins in cere-
bella of mutant mice, and the median increase was mild, about
56% (Supplementary Material, Fig. S2). These mice also have
a mild neurobehavioral phenotype, and a mild amount of neuro-
degeneration. Similarly, we do not see a difference in iba1-
positive microglia at baseline; the effect is once again mild
and is only visible and significant when provoked with an experi-
mental inflammogen (LPS). Thus, either as a cause or effect of
the mild rise in oxylipins, there is more ‘inducibility of inflam-
mation’ in the mutant mice. Furthermore, active microglia has
been shown to produce ROS, mainly nitrogen oxide further ex-
acerbating the problem (44). Telomere length, an indirect
marker of inflammation, was also measured in Friedreich’s
patient plasma correlating disease duration with reduction in
telomere lengths (50–52). These cases represent the need for
further research concerning inflammation as a possible pathome-
chanism of FRDA.
Figure 6. Cerebellum of frataxin-deficient KIKO mouse model has increased activation of transcription factors CREB and AP1. (A and B) KIKO shows 3.67-
and 1.52-fold increase of CREB and AP1 activation, respectively. Activation is marked by phosphorylation. Bars represent averages+ standard deviations
(n ¼ 6, P , 0.05∗, P , 0.005∗∗).
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In conclusion, we have shown in cerebellum of frataxin-
deficient mouse models KIKO and YG8, and patient derived
lymphocytes, that frataxin deficiency leads to increased activa-
tion of transcription factors CREB and AP1 mediating the over-
expression of COX2 subsequently elevating concentrations of
multiple prostanoids, and that cerebella of such mice are more
sensitive to a neuroinflammatory stimulus (Fig. 7). Further
studies are necessary to understand the extent to which
neurodegeneration of dorsal root ganglion and cerebellum in
FRDA is caused by prostanoid alteration, and if the causal regula-
tory changes are due to chronic elevation of ROS. If prostanoid
synthesis is involved in the pathogenesis of FRDA, anti-
inflammatory treatments targeting COX, or upstream transcrip-
tion factors CREB and AP1 may open new avenues for FRDA
treatment.
MATERIAL ANDMETHODS
Cell culture
Human B-lymphocyte cells; GM16220, GM16197, GM15851,
GM15850, GM04079, GM00607, GM00333 and GM00130
(Coriell Institute) were maintained at 378C in humidified atmos-
phere with 5% CO2. DMEM (Cellgro) supplemented with 15%
fetal bovine serum (JR-Scientific), 2 mM sodium pyruvate (Sigma-
Aldrich), 1× antibiotic-antimycotic, 1× MEM non-essential
amino acids (Gibco), and 50 mg/ml uridine (MP-Biomedicals)
was used to grow cells.
Mouse models and dissection
Human transgenic frataxin-deficient mice YG8 (15) (YG8Pook/
J; Jackson Laboratory, Sacramento, CA, USA) and endogenous
frataxin-deficient KIKO mice [a kind gift from Dr. Pandolfo
(29)] were housed in a vivarium maintained at 22–248C and
40–60% relative humidity with a 12-h light/12-h dark cycle.
All experimental procedures were approved by the University
of California Institutional Animal Care and Use Committee.
The mice were decapitated and cerebellums were immediate-
ly removed and then flash frozen with liquid nitrogen. Samples
were stored in2808C until utilized for mass spectrometry, quan-
titative PCR, western blot and COX activity assay.
RNA extraction and quantitative RT–PCR
Total RNA was extracted from cerebellar tissue of frataxin-
deficient KIKO and YG8 mice as well as B-lymphocyte cells
using RNeasy plus mini kit (Qiagen) following manufacturer’s
instruction and RNA quantity measured by NanoDrop 2000c
Spectrophotometer (Thermo Scientific).
Quantitative PCR was performed using the Superscript III
One Step kit (Invitrogen) per manufacturer’s instruction in a
Roche Lightcycler 480 (Roche Diagnostics). Primer sequences
are b-actin Forward GCCAACACAGTGCTGTCTGG, b-actin
Reverse CTGCTTGCTGATCCACATCTGC, YG8 FXN Forward
CTGGCTATCTTCTCCATCCAG, YG8 FXN Reverse AGCA
TCTTTTCCGGAATAGGC, KIKO Fxn Forward GATCAA
CAAGCAGACCCCAAA, KIKO Fxn Reverse AGGCCAATG
AAGACAAGTCCA, B-Lymphocyte FXN Forward ATCTT
CTCCATCCAGTGGACCT and B-Lymphocyte FXN Reverse
GCTGGGCATCAAGCATCTTTT. The data were analyzed
by delta delta CT method.
Protein extraction and western blot analysis
Mouse cerebellar tissues and B-lymphocyte cell pellets were
homogenized with a cell lysis buffer (Cell Signaling) with Halt
phosphatase inhibitor (Thermo-Fisher), complete protease
Figure 7. Frataxin-deficient YG8 hemizygote mouse cerebellum shows
increased inducibility of inflammation with LPS treatment compared with WT.
(A) Immunohistochemistry of frataxin-deficient YG8 hemizygote and WT cere-
bellar section with antibody specific to Iba1. The LPS treatment has increased the
protein concentration of Iba1 in mutants 1.37-fold compared with WT which
increased 1.16-fold from similar baseline expression in the PBS treatment. (B)
Quantification of immunohistochemistry. Bars represent averages+ standard
deviations (n ¼ 4, P , 0.05∗, P , 0.005∗∗).
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inhibitors (Roche) and PSMF (Sigma-Aldrich). Thirty micro-
grams of lysates were loaded into 4–12% Bis–Tris gels (Invitro-
gen). Electrophoresis was carried out according to the
manufacturer’s recommendations. Following electrophoresis,
the proteins were transferred to nitrocellulose membranes by the
iBlot device (Invitrogen), blocked with an Odyssey blocking
buffer (LI-COR Biotechnology) for 1 h. Membranes were incu-
bated overnight with the following primary antibodies in blocking
buffer: COX1 (ab133319 for human, ab133319 for mouse;
Abcam), COX2 (ab62331 for human, ab6665 for mouse;
Abcam), phospho-CREB (4095), phospho-cJun/AP1 (5464),
phospho-NFkB (4025; Cell signaling), cPLA2 (sc-454),
phospho-cPLA2 (sc-34391; Santa Cruz Biotech, Santa Cruz,
CA, USA), b-actin (A5441; Sigma-Aldrich), and b-tubulin
(DSHB-E7; DSHB, Iowa). Subsequently, the membranes were
incubated with a corresponding pair of IRDye 680CW and
IRDye 800CW-coupled secondaryantibodies (LI-COR). Proteins
were visualized with the Odyssey infrared imager and software
(LI-COR) according the manufacturer’s instruction.
LPS administration and immunostaining of Iba1
Female YG8 mice or C57BL/6 mice were intraperitoneally
injected with a single dose of LPS (5 mg/kg). Mice were per-
fused with 4% paraformaldehyde in 0.1 M PBS at 24 h after
LPS injection. The animals were anesthetized and then perfused
with 4% paraformaldehyde in 0.1 M PBS (pH 7.4) and cryopro-
tected in 30% sucrose in 0.1 M PBS. 15 mm coronal brain sec-
tions from cerebellum were cut by cryostat. Representative
sections were stained with Iba1 antibody (1:100; Wako, VA,
USA) followed by a fluorescent secondary antibody (Invitrogen,
NY, USA). The images of Iba1 fluorescent immunostaining
were taken with Nikon camera (Tokyo, Japan). Fluorescent in-
tensity from six fields of each animal was measured by Image
J software.
COX activity
Total COX activity was measured with COX Fluorescent Activ-
ity Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) accord-
ing to manufacturer’s instruction normalized to samples
incubated with Indomethacin (Sigma-Aldrich).
Tissue extraction
Frozen mouse cerebellar samples (20–100 mg) were pulverized
on dry ice, after mixing with 5 ml BHT/EDTA (0.2 mg/ml in 1:1
methanol/water), and 30 ml methanolic surrogate solutions con-
taining a suite of labeled surrogates to quantify cholesteryl ester,
triglyceride, phospholipid, free fatty acid, prostanoid, throm-
boid, diol, alcohol, epoxide and sphingoid bases. Samples
were introduced to two pre-cleaned stainless steel balls and vor-
texed with 500 ml methanol for 3 min. Samples were pelleted by
centrifugation for 5 min at 10 000 rcf, 108C, and the supernatant
was isolated. Residues were mixed with 350 ml 2-propanol,
homogenized and pelleted and the supernatant was combined
with the primary methanolic extract. The residue was extracted
a third time with 350 ml cyclohexane, followed by mixing and
supernatant isolation and combination with the other organic iso-
lates. Solvents were removed by vacuum evaporation for 60 min
without heating and reconstituted in 100 ml toluene and mixed
with 100 ml methanol. A 10 ml aliquot of the extract was isolated
for fatty acid analyses while 180 ml were evaporated to dryness
and reconstituted in 100 ml methanol containing 1-cyclohexyl-
3-ureido-dodecanoic acid (CUDA), filtered at with Amiconw
Ultrafree-MC Durapore PVDF0.1 mm filters (Millipore,Billerica,
MA, USA) and used for the quantification of oxylipins.
UPLC-tandem mass spectrometry
Analytes were separated by reverse phase ultra-performance
liquid chromatograph with a 1.7 mm Acquity BEH column
Figure 8. Model for frataxin deficiency with elevation of prostanoids leading to neurodegeneration of dorsal root ganglion (DRG) and cerebellum (CBLM).
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(Waters, Milford, MA, USA) using a 16 min gradient (Solvent
A ¼ 0.1% acetic acid; Solvent B ¼ 90:10 v/v acetonitrile/
isopropanol), detected on an API 4000 QTrap (AB Sciex, Fra-
mingham, MA, USA) by multiple reaction monitoring after
negative mode electrospray ionization, and quantified against
6 point calibration curves using internal standard methodologies
as previously reported (doi:10.1371/journal.pone.0089393).
Data reporting criteria include: data .3:1 signal to noise; the
relative contribution of background from method blanks is
,25% of signal; values are within the calibrated linear range.
Data analysis
Quantified results were manually curated to confirm accurate
integrations. NEFA results for a single sample (ID#1) were stat-
istical outliers by the Dixon’s Q-test and were excluded. All
missing values were computationally imputed using a probabil-
istic principal components analysis (PCA). Data were trans-
formed to normality prior to statistical analyses using the
procedures of Box and Cox. Differences in means were deter-
mined using 2-tailed T-tests or Mann–Whitney U-tests if nor-
mality was not achieved. The effects of frataxin gene on lipid
profiles were assessed using multivariate analyses including corre-
lations, cluster analyses and principal components analyses.
Statistical operations were performed within Microsoft Excel.
Multivariate and non-parametric statistics were performed using
the Excel Add-In imDEV v1.4.2 (http://sourceforge.net/apps/
mediawiki/imdev/index.php?title=Main_Page), which provides
a graphical user interface to R-Programing language statistical
packages (doi: 10.1093/bioinformatics/bts439).
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